Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
board room table surrounded by empty chairs
The board purchases show their confidence in the company's future

Cellmid Ltd (ASX:CDY) has had four of its board members purchase company stock recently with one member buying $1 million worth of shares.

The share purchases were made in a variety of ways including on-market trades and participation in the recent share placement and share purchase plan (SPP).

The board members that increased their holdings were managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck.

Eck acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

consumer health segment overview
September 17 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use